1932

Abstract

Societal expectations about drug safety and efficacy are rising while productivity in the pharmaceutical industry is falling. In 2004, the US Food and Drug Administration introduced the Critical Path Initiative with the intent of modernizing drug development by incorporating recent scientific advances, such as genomics and advanced imaging technologies, into the process. An important part of the initiative is the use of public-private partnerships and consortia to accomplish the needed research. This article explicates the reasoning behind the Critical Path Initiative and discusses examples of successful consortia.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.med.59.090506.155819
2008-02-18
2024-06-25
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.med.59.090506.155819
Loading
/content/journals/10.1146/annurev.med.59.090506.155819
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error